Cell therapy manufacturing market features an intensive study of today's market landscape and potential future opportunities associated with cell therapy manufacturing as a whole. It examines both contract manufactures, and developmental companies with in-house production facilities, providing in depth discussions of the different business entities currently engaged in this field, across different international markets. It also covers new directions like drug manufacturing which will likely emerge as a major force in the cell therapy market in the next few years. It looks at the regulatory environment in different countries and examines how these factors may impact cell therapy manufacturing.
Market Dynamics
High prevalence of cancer is expected to propel growth of the cell therapy manufacturing market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, approval and launch of CAR T-cell therapies is also expected to aid in growth of the market. For instance, in March 2020, Tessa Therapeutics received the U.S. Food and Drug Administration (FDA)’s Regenerative Medicine Advanced Therapy designation to its investigational CD30-targeted CAR T-cell therapy for the treatment of relapsed or refractory classical Hodgkin’s lymphoma.
Increasing investment in cell therapy is expected to offer lucrative growth opportunities for players in the cell therapy manufacturing market. For instance, in January 2020, RootPath, a preclinical-stage biotechnology company focused on developing personalized, highly-potent T cell therapy using its proprietary Synthetic Immunology Platform, raised US$ 11 million in Series A funding round. Moreover, R&D in cell therapy is also expected to aid in growth of the market. For instance, in May 2020, TolerogenixX GmbH announced the publication of positive Phase Ib results of its lead product MIC-Lx, a cell therapy product that can induce donor-specific tolerance in kidney transplant recipients, in The Journal of Clinical Investigation.
Competitive Analysis
Major players operating in the cell therapy manufacturing market include, Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher Scientific, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices, and WuXi AppTec.
Major players operating in the cell therapy manufacturing market are focused on launching new products to expand their product portfolio. For instance, in October 2020, Thermo Fisher Scientific launched its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing.
In-depth Report on Cell Therapy Manufacturing Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/cell-therapy-manufacturing-market-1728
No comments:
Post a Comment